课题基金 / 基金详情

项目摘要

项目成果

Mingji Dai的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract The goal of our research program is to innovate in both the strategy and methodology of organic synthesis, and apply them to solve problems of biological and medicinal importance and ultimately impact human health. Our program focuses on synthesis and study of both natural (Project 1A-C) and unnatural (Project 2) molecules with particular potential for the treatment of cancer, neurological disorders, and drug resistant infectious diseases. In project 1, we aim to synthesize lyconadin alkaloids (1A), bridged macrolides (1B), and polycyclic diterpene (1C) natural products and their analogs and identify compounds based on these privileged scaffolds for novel therapeutic development. In project 2, we aim to develop novel and practical amphoteric diamination methodologies including the enantioselective versions to provide new avenues toward N- heterocycles including piperazine, 1,4-diazepane, 1,4-diazocane, and related macrocyclic compounds with significantly increased substitution diversity on the carbon atoms. The selected natural molecules represent both the state of the art challenges for complex molecule synthesis as well as potential novel therapeutics for various human diseases. However, access of these natural products and their analogs are extremely difficult, which significantly hampered their biomedical development. The N-heterocycles are indispensable structural motifs in medicinal chemistry and exist in many lifesaving drug molecules. However, the substituents are generally limited on the nitrogen atoms and there is a significant lack of substitution diversity on the carbon atoms due to the limitations of the current synthetic methodologies. Our research program will address these gaps. The expected outcomes of this research will provide (i) new reactions and strategies in the toolbox of both medicinal chemists and synthetic chemists to prepare functional molecules, (ii) a collection of medicinally relevant molecules featuring structural novelty, complexity, and diversity for further and larger biological evaluations in academic institutions and pharmaceutical industries, and (iii) novel anticancer, anti- neurodegenerative and antimicrobial lead compounds with potentially novel mode of actions for in vivo and clinical evaluations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Purdue Drug Discovery Training Program
  • 批准号:
    10186773
  • 项目类别:
  • 资助金额:
    $19.51万
  • 财政年份:
    2019
  • 负责人:
    Mingji Dai
  • 依托单位:
Synthesis and Study of Medicinally Important Molecules
  • 批准号:
    10216307
  • 项目类别:
  • 资助金额:
    $38.18万
  • 财政年份:
    2018
  • 负责人:
    Mingji Dai
  • 依托单位:
Synthesis and Study of Medicinally Important Molecule
  • 批准号:
    10685687
  • 项目类别:
  • 资助金额:
    $38.18万
  • 财政年份:
    2018
  • 负责人:
    Mingji Dai
  • 依托单位:
Synthesis and Study of Medicinally Important Molecules
  • 批准号:
    9755457
  • 项目类别:
  • 资助金额:
    $38.18万
  • 财政年份:
    2018
  • 负责人:
    Mingji Dai
  • 依托单位:
国内基金
海外基金
Iboga alkaloids骨架导向的不对称串联反应构建吖庚环并[4,5-b]吲哚及其在全合成中的应用
  • 批准号:
    21801032
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2018
  • 负责人:
    陈惠渝
  • 依托单位: